Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Literature
1.
Wright KD, Panetta JC, Onar-Thomas A et al (2014) Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-014-2614-6
2.
Cohen IJ (2004) Defining the appropriate dosage of folinic acid after high dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Oncol 26:156–163CrossRef
3.
Cohen IJ, Wolff JE (2014) How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer 61:7–10CrossRefPubMed
4.
Bonda-Shkedi E, Arush MW, Kaplinsky C et al (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. J Pediatr Hematol Oncol 35(4):271–275CrossRefPubMed
5.
Metadata
Title
Delayed methotrexate excretion in infants and young children with central nervous system tumors and postoperative fluid collections
Author
Ian Cohen
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2684-0

Other articles of this Issue 4/2015

Cancer Chemotherapy and Pharmacology 4/2015 Go to the issue

Original Article

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

Original Article

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Original Article

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

Letter to the Editor

Response to: comment on “Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections”

Original Article

Stabilization of the Karenitecin ® lactone by alpha-1 acid glycoprotein

Original Article

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits